Medical cannabis company Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), has announced the appointment of Franziska Katterbach as President, Khiron Europe to replace Tejinder Virk, who has resigned from the company.

Hired in October 2019 to the role of Managing Director and Chief Legal Counsel, Khiron Europe, Katterbach’s promotion to the position of President aligns with the company’s commitment to diversity and inclusion throughout the organization, including at the executive level, the company said in a statement.

“I would like to congratulate Franziska on her appointment, which comes at a very exciting time for our European team. Since joining Khiron, Franziska has been a driving force behind our European operations. Her regulatory expertise, strong leadership skills and exceptional day-to-day management of operations have allowed us to develop a differentiated, asset-light platform. Most recently, the European team launched another new product into the German market while more than tripling shipment volumes, demonstrating strong execution in Europe’s largest market,” said Alvaro Torres, CEO and Director.

Franziska Katterbach herself added: “I am a great believer in Europe’s medical cannabis market and am honored to lead our world-class team as we expand patient access, along with our market presence, in Germany and the UK. On behalf of the Company, I would like to thank Tejinder for his many contributions to our European operations and wish him well in his future endeavors.”

Tejinder Virk left the company to head Akanda, formerly known as Halo Collectives, with operations in Lesotho. His resignation will result in the forfeiture of 2.2 million stock options and 600,000 restricted share units previously awarded.

See also: Khiron Life Sciences CEO Álvaro Torres Discusses The Cannabis Company’s Unique Go-To-Market Strategy & Its Network Of Zerenia Integrative Care Clinics